background
role
respiratori
virus
cystic
fibrosi
cf
exacerb
incomplet
understood
method
crosssect
studi
cf
children
pulmonari
exacerb
midturbin
swab
test
direct
immunofluoresc
antibodi
assay
multiplex
pcr
panel
resplex
ii
qiagen
resplex
ii
also
appli
sputum
throat
swab
sampl
pulmonari
function
test
qualiti
life
sever
score
record
sputum
cell
count
bacteri
densiti
cytokin
measur
result
subject
test
posit
least
one
respiratori
viru
diagnost
method
appli
sampl
type
virusposit
patient
younger
p
like
male
p
higher
cf
clinic
sever
p
lower
qualiti
life
physic
score
p
similar
neutrophil
percentag
elastas
level
conclus
compar
nonvir
exacerb
viralrel
exacerb
associ
wors
sever
qualiti
life
score
similar
pulmonari
inflamm
cystic
fibrosi
cf
affect
patient
worldwid
bacteri
infect
main
caus
recurr
pulmonari
exacerb
lead
progress
lung
damag
less
known
role
viral
respiratori
tract
infect
true
impact
respiratori
virus
cf
may
previous
underestim
major
previou
studi
use
viral
cultur
andor
immunofluoresc
techniqu
rel
insensit
restrict
breadth
viral
detect
date
publish
report
respiratori
viral
infect
children
cf
primarili
focus
proport
pulmonari
exacerb
associ
virus
relationship
sever
exacerb
infect
statu
respiratori
virus
assess
extent
complic
mediat
direct
viral
effect
via
potenti
bacteri
colon
infect
unclear
pulmonari
manifest
cf
involv
neutrophildomin
airway
inflamm
chronic
bacteri
infect
although
tempor
relationship
infect
inflamm
remain
unclear
earli
diseas
later
diseas
selfperpetu
cycl
airway
obstruct
chronic
bacteri
infect
vigor
inflamm
result
structur
damag
airway
less
current
known
contribut
viral
infect
better
understand
host
inflammatori
respons
follow
respiratori
viral
infect
may
minim
use
prolong
antibiot
therapi
primari
object
studi
investig
proport
cf
pulmonari
exacerb
associ
respiratori
viral
infect
detect
convent
diagnost
commerci
avail
multiplex
molecular
diagnost
assay
secondari
object
determin
clinic
sever
pulmonari
inflamm
due
exacerb
associ
viral
infect
novemb
march
conduct
observ
crosssect
studi
children
cf
seen
set
pulmonari
exacerb
patient
recruit
respiratori
medicin
clinic
hospit
sick
children
larg
pediatr
referr
center
care
approxim
cf
patient
enrol
cf
patient
met
follow
inclus
criteria
age
b
year
clinic
present
consist
pulmonari
exacerb
defin
follow
clinic
symptom
chang
sputum
product
increas
cough
dyspnea
alon
combin
temperatur
andor
chang
respiratori
statu
tachypnea
indraw
wheez
crackl
report
attend
team
inform
consent
assent
child
appropri
obtain
particip
ethic
approv
obtain
research
ethic
board
hospit
sick
children
exclus
criteria
includ
lack
consent
insuffici
command
english
absenc
translat
inform
patient
demograph
cfrelev
baselin
characterist
cfrelat
comorbid
bacteri
colon
abstract
health
record
cystic
fibrosi
questionnairerevis
cfqr
cystic
fibrosi
clinic
score
cfc
prospect
administ
particip
standard
interview
physic
assess
cfc
acut
clinic
score
base
sign
symptom
chosen
sever
scale
reliabl
eas
use
bodi
mass
index
bmi
percentil
calcul
children
year
age
weightforrecumb
length
percentil
age
midturbin
flock
swab
copan
diagnost
murrietta
ca
collect
enrol
patient
place
ml
univers
transport
medium
utmrt
copan
diagnost
murrieta
ca
addit
children
old
enough
produc
sputum
provid
sputum
sampl
floq
copan
throat
swab
inocul
utm
obtain
unabl
produc
sputum
refer
fig
sampl
collect
test
midturbin
specimen
examin
direct
fluoresc
antigen
assay
dfa
respiratori
virus
also
appli
resplex
ii
panel
floq
copan
throat
swab
sputolysin
mgml
calbiochem
treat
sputum
sampl
ensur
sputolysin
would
affect
perform
assay
fig
evalu
potenti
interfer
sputolysin
effici
nucleic
acid
extract
perform
assay
randomli
chose
four
known
posit
midturbin
sampl
rsv
b
piv
hrvinfa
rsva
anoth
studi
divid
two
equal
aliquot
potenti
interfer
sputolysin
test
midturbin
swab
instead
sputum
sampl
non
sputolysintr
sputum
sampl
would
enabl
appropri
nucleic
acid
extract
sputum
viscos
mix
one
aliquot
equal
volum
sputolysin
pb
phosphat
buffer
salin
equal
volum
pb
alon
incub
min
room
temperatur
extract
total
nucleic
acid
aliquot
nuclisen
easymag
biomerieux
st
laurent
qc
canada
follow
amplif
resplex
ii
assay
patient
classifi
virusposit
respiratori
viru
detect
midturbin
throat
sputum
sampl
one
three
assay
use
dfa
resplex
ii
rtpcr
sputum
sampl
underw
bacteri
densiti
analysi
pseudomona
aeruginosa
staphylococcu
aureu
haemophilu
influenza
base
predomin
organ
isol
routin
bacteri
cultur
use
previous
describ
method
level
addit
inflammatori
cytokin
pdgf
b
ra
eotaxin
fgf
gcsf
gmcsf
ifng
rant
tnfalpha
vegf
measur
sputolysintr
sputum
sampl
use
commerci
multiplex
beadbas
assay
bioplex
cytokin
assay
biorad
detect
rang
cytokin
pgml
per
manufactur
guidelin
neutrophil
elastas
ne
activ
measur
use
modifi
enzymat
assay
base
ne
cleavag
nitroanilid
nmethoxysuccinylalaalaprovalpnitroanilid
result
report
unitsml
unit
mmolmin
lower
limit
detect
unitsml
sputum
neutrophil
percentag
percentag
neutrophil
base
count
white
blood
cell
children
old
enough
perform
spirometri
standard
spirometri
done
enrol
routin
everi
visit
report
forc
expiratori
volum
fev
percentag
predict
valu
sex
height
use
equat
corey
et
al
defin
baselin
fev
best
fev
month
prior
current
pulmonari
exacerb
exacerb
fev
fev
time
present
pulmonari
exacerb
standard
descript
compar
statist
use
data
categor
viral
infect
statu
virusposit
virusneg
patient
normallydistribut
continu
variabl
total
bacteri
densiti
bacteri
densiti
resplex
ii
virus
patient
old
enough
produc
sputum
throat
swab
aureu
p
aeruginosa
h
influenza
calcul
mean
analyz
differ
compar
group
use
student
ttest
skew
data
age
obes
measur
predict
cfsc
cfqr
score
level
sputum
neutrophil
percentag
count
sputum
neutrophil
elastas
deriv
median
use
mannwhitney
method
comparison
test
fisher
exact
test
use
compar
categor
variabl
group
appropri
use
standard
formula
estim
sensit
specif
respect
binomi
confid
interv
ci
midturbin
swab
sputum
sampl
throat
swab
viru
detect
rel
combin
sampl
type
refer
standard
differ
test
perform
calcul
use
mcnemar
test
p
valueb
consid
statist
signific
data
analyz
spss
statist
softwar
version
spss
inc
chicago
il
usa
total
cf
patient
screen
inclus
studi
novemb
march
met
elig
criteria
declin
particip
studi
among
enrol
patient
classifi
virusposit
midturbin
swab
either
sputum
sampl
throat
swab
one
three
assay
use
dfa
rtpcr
multiplex
pcr
virusposit
subject
test
posit
one
viru
remain
two
virus
resplex
ii
particip
test
posit
one
respiratori
viru
coxsackieechoviru
commonli
identifi
pathogen
tabl
rsv
report
particip
test
posit
two
virus
tabl
virusposit
patient
significantli
younger
p
like
male
p
virusneg
patient
also
significantli
like
present
fever
p
upper
respiratori
tract
infect
symptom
p
tabl
signific
differ
two
group
time
exacerb
virusposit
patient
significantli
higher
cf
clinic
score
cfc
vs
p
lower
qualiti
life
physic
cfqr
score
vs
p
tabl
patient
viral
infect
statu
determin
without
incorpor
posit
rhinoviru
coxsackieechoviru
result
physic
cfqr
score
virusposit
patient
remain
significantli
lower
vs
p
howev
cfc
longer
significantli
differ
virusposit
neg
patient
antibiot
use
hospit
requir
mean
percent
predict
exacerb
significantli
differ
two
group
tabl
bacteri
densiti
examin
sputum
sampl
virusposit
virusneg
patient
mean
total
bacteri
densiti
observ
virusposit
patient
two
log
lower
albeit
statist
signific
found
virusneg
patient
vs
cfuml
p
virusposit
neg
patient
similar
neutrophil
percentag
neutrophil
elastas
level
tabl
also
differ
addit
cytokin
level
group
supplementari
tabl
total
patient
concomit
sputum
sampl
concomit
throat
swab
test
respiratori
virus
resplex
ii
overal
detect
rate
respiratori
virus
use
midturbin
swab
similar
throat
swab
vs
higher
sputum
sampl
vs
supplementari
tabl
classif
infect
statu
base
detect
least
one
respiratori
viru
midturbin
swab
concord
rate
sputum
sampl
concord
pair
positiveposit
negativeneg
discord
pair
positiveneg
neg
posit
concord
rate
throat
swab
concord
pair
positiveposit
negativeneg
discord
pair
positiveneg
negativeposit
sensit
midturbin
swab
sputum
sampl
rel
combin
midturbin
andor
sputum
sampl
ci
ci
respect
specif
ci
tabl
identifi
virus
among
virusposit
subject
identifi
diagnost
method
appli
sampl
midturbin
swab
throat
swab
sputum
sampl
singl
midturbin
swab
trend
toward
sensit
sputum
sampl
p
calcul
sensit
specif
midturbinatethroat
swab
pair
sampl
due
limit
number
proport
virusassoci
exacerb
document
studi
similar
demonstr
recent
studi
use
molecularbas
techniqu
significantli
higher
found
prior
studi
use
convent
diagnost
method
discrep
attribut
higher
sensit
broader
rang
viru
detect
afford
molecularbas
method
lead
better
estim
true
preval
respiratori
virus
cf
exacerb
rhinovirus
report
major
pathogen
cf
exacerb
detect
rate
reach
sampl
collect
exacerb
routin
visit
anoth
studi
report
similar
rate
rhinoviru
detect
vs
sampl
collect
exacerb
rhinoviru
coxsackieechoviru
compris
half
identifi
virus
given
resplex
ii
assay
suboptim
perform
distinguish
rhinoviru
coxsackieechoviru
true
rate
rhinoviru
detect
might
even
higher
studi
document
low
proport
even
though
conduct
larger
second
wave
influenza
modest
vaccin
uptak
rate
anoth
studi
conduct
typic
influenza
season
report
higher
influenza
b
detect
rate
despit
high
influenza
vaccin
uptak
discrep
may
relat
perfect
match
vaccin
circul
influenza
virus
studi
period
compar
anoth
studi
rate
viral
coinfect
significantli
higher
vs
discrep
attribut
broader
rang
viru
detect
afford
resplex
ii
assay
compar
molecularbas
method
use
studi
detect
virus
vs
virus
multiplex
assay
permit
improv
identif
case
infect
multipl
agent
although
impact
multipl
viral
infect
clinic
cours
diseas
present
unknown
worthi
studi
knowledg
first
studi
assess
sever
viralassoci
pulmonari
exacerb
impact
qualiti
life
virusposit
subject
significantli
higher
sever
lower
qualiti
life
score
abil
detect
differ
sever
score
two
group
metric
pulmonari
exacerb
sever
may
reflect
increas
statist
power
afford
quantit
natur
sever
qualiti
life
score
anoth
studi
suggest
children
viru
rhinoviru
coxsackieechoviru
identifi
significantli
greater
declin
baselin
compar
children
rhinoviru
infect
howev
repeat
analys
exclud
rhinoviru
coxsackieechovirusposit
patient
chang
find
differ
cfc
becam
insignific
might
reflect
decreas
discrimin
abil
cfc
compar
cfqr
underpow
sampl
size
exclud
rhinoviru
coxsackieechovirusposit
patient
andor
bias
estim
result
miss
cfqr
data
sever
studi
correl
repeat
bacteri
infect
cf
patient
increas
airway
inflamm
wherea
pathophysiolog
virusinduc
cf
exacerb
remain
unclear
studi
level
sputum
neutrophil
percentag
neutrophil
elastas
within
rang
publish
data
wherea
sputum
neutrophil
cell
count
lower
describ
literatur
studi
includ
outpati
milder
exacerb
consist
younger
patientpopul
may
result
milder
degre
airway
inflamm
therefor
lower
sputum
neutrophil
count
also
found
level
inflammatori
cytokin
group
similar
report
twolog
lower
mean
total
bacteri
densiti
virusposit
subject
compar
virusneg
one
albeit
signific
like
due
younger
age
virusposit
subject
recent
studi
report
trend
toward
lower
cytokin
product
cf
airway
epitheli
cell
follow
viral
infect
whether
respiratori
virus
interact
bacteria
induc
observ
inflamm
remain
controversi
requir
investig
data
avail
optim
method
respiratori
viral
detect
limit
controversi
studi
report
higher
rate
viral
detect
midturbin
swab
sputum
sampl
contrast
anoth
recent
studi
report
higher
concord
rate
rhinovirus
detect
viru
type
differ
time
sampl
studi
sampl
collect
exacerb
exacerb
might
contribut
observ
differ
larger
studi
compar
test
perform
characterist
pair
upper
airway
sputum
sampl
collect
exacerb
would
provid
insight
find
studi
sever
limit
observ
design
limit
abil
exclud
effect
measur
unmeasur
covari
analysi
despit
central
import
pulmonari
exacerb
outcom
measur
cf
clinic
trial
standard
definit
pulmonari
exacerb
includ
children
age
valid
use
broader
definit
pulmonari
exacerb
includ
children
manag
outpati
sampl
may
includ
patient
mild
exacerb
studi
howev
proport
hospit
patient
viral
infect
studi
similar
outpati
likewis
gener
accept
sever
score
pulmonari
exacerb
appli
younger
children
includ
cfqr
valid
wide
use
patientreport
outcom
despit
valid
pft
gold
standard
cfc
infrequ
use
clinic
trial
highlight
need
evalu
applic
clinic
studi
small
sampl
size
permit
subgroup
analys
accord
individu
virus
final
data
viral
infect
statu
cf
children
experienc
exacerb
compar
strengthen
associ
exacerb
viral
infect
compar
virus
rsv
rhinovirus
shed
prolong
period
week
vs
week
may
acquir
exacerb
howev
virusposit
subject
like
present
fever
upon
exacerb
conclus
respiratori
virus
especi
coxsacki
echoviru
rhinoviru
frequent
associ
pulmonari
exacerb
pediatr
cf
patient
systemat
detect
respiratori
virus
molecular
techniqu
use
midturbin
swab
occur
set
pulmonari
exacerb
rel
contribut
repeat
respiratori
viral
infect
young
children
pulmonari
inflamm
continu
declin
lung
function
seen
earli
age
known
longitudin
studi
document
declin
fev
time
comprehens
evalu
patient
viral
bacteri
infect
exacerb
might
help
clarifi
contribut
respiratori
virus
progress
lung
damag
supplementari
data
articl
found
onlin
http
author
financi
form
conflict
interest
provid
qiagen
dr
susan
e
richardson
receiv
honoraria
qiagen
luminex
molecular
diagnost
studi
multiplex
respiratori
pcr
children
fund
agenc
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
